@article{f4b5284f509b402c9c11ea292acaa76d,
title = "Neural correlates of impulsivity in healthy males and females with family histories of alcoholism",
abstract = "Individuals family-history positive (FHP) for alcoholism have increased risk for the disorder, which may be mediated by intermediate behavioral traits such as impulsivity. Given the sex differences in the risk for and clinical presentation of addictive disorders, risk for addiction may be differentially mediated by impulsivity within FHP males and females. FHP (N=28) and family-history negative (FHN, N=31) healthy, non-substance-abusing adults completed an fMRI Go/No-Go task and were assessed on impulsivity and alcohol use. Effects of family history and sex were investigated as were associations between neural correlates of impulse control and out-of-scanner measures of impulsivity and alcohol use. FHP individuals showed greater activation in the left anterior insula and inferior frontal gyrus during successful inhibitions, an effect that was driven primarily by FHP males. Higher self-reported impulsivity and behavioral discounting impulsivity, but not alcohol use measures, were associated with greater BOLD signal in the region that differentiated the FHP and FHN groups. Impulsivity factors were associated with alcohol use measures across the FHP and FHN groups. These findings are consistent with increased risk for addiction among FHP individuals being conferred through disrupted function within neural systems important for impulse control.",
keywords = "addiction, family history of alcoholism, impulsivity, inferior frontal gyrus (IFG), insula, sex differences.",
author = "Devito, \{Elise E.\} and Meda, \{Shashwath A.\} and Rachel Jiantonio and Potenza, \{Marc N.\} and Krystal, \{John H.\} and Pearlson, \{Godfrey D.\}",
note = "Funding Information: JHK consults for: Aisling Capital, Astellas Pharma Global Development, AstraZeneca Pharmaceuticals Biocortech, Brintnall \& Nicolini, Easton Associates, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Lundbeck Research USA, Medivation, Merz Pharmaceuticals, MK Medical Communications, F. Hoffmann-La Roche, Sage Therapeutics, SK Holdings, Sunovion Pharmaceuticals, Takeda Industries, Teva Pharmaceutical Industries; serves on the Board of Directors for the Coalition for Translational Research in Alcohol and Substance Use Disorders, as President Elect of the American College of Neuropsycho-pharmacology, and as Editor of Biological Psychiatry; is on the Scientific Advisory Boards for Abbott Laboratories, Bristol-Myers Squibb, CHDI Foundation, Eisai, Eli Lilly and Forest Laboratories, Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Naurex, Pfizer Pharmaceuticals, Shire Pharmaceuticals, StratNeuro Research Program at Karolinska Institute (International Advisory Board); is employed by Yale University School of Medicine and VA CT Healthcare System; holds patents for the following: (1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. Patent \#:5 447 948.September 5, 1995, (2.) co-inventor with Dr Gerard Sanacora on a filed patent application by Yale University related to targeting the glutamatergic system for the treatment of neuropsychiatric disorders (PCTW O06108055A1), (3) Intranasal Administration of Ketamine to Treat Depression (patent pending). MNP reports no financial conflicts of interest with respect to the content of this manuscript yet has received financial support or compensation for the following: consulted for and advised Boehringer Ingelheim; consulted for and has financial interests in Somaxon; received research support from the National Institutes of Health, Veteran{\textquoteright}s Administration, Mohegan Sun Casino, the National Center for Responsible Gaming and its affiliated Institute for Research on Gambling Disorders, and Forest Laboratories, Ortho-McNeil, Oy-Control/Biotie, Glaxo-SmithKline, and Psyadon pharmaceuticals; participated in surveys, mailings or telephone consultations related to drug addiction, impulse-control disorders or other health topics; consulted for law offices and the federal public defender{\textquoteright}s office in issues related to impulse-control disorders; provides clinical care in the Connecticut Department of Mental Health and Addiction Services Problem Gambling Services Program; performed grant reviews for the National Institutes of Health and other agencies; guest-edited journal sections; given academic lectures in grand rounds, CME events and other clinical or scientific venues; and generated books or book chapters for publishers of mental health texts. The remaining authors declare no conflicts of interest. Funding Information: This research was supported by National Institute on Alcohol Abuse and Alcoholism (NIAAA), 2P50 AA 012870, Center for Translational Neuroscience on Alcoholism and US Department of Veterans Affairs Alcohol Research Center, RO1 DA020709 from National Institute on Drug Abuse (NIDA). EED was supported by T32 AA015496 from NIAAA and K12 DA031050 from NIDA, NIAAA, Office of Research on Women{\textquoteright}s Health (ORWH) and NIH Office of the Director (OD). MNP was supported by P20 DA027844 from NIDA and RL1 AA017539 from NIAAA. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIAAA, NIDA, or NIH. Funding bodies had no role in the collection, analysis, or the decision to publish these data. We thank Dr Sharna Jamadar for her helpful technical assistance.",
year = "2013",
month = sep,
doi = "10.1038/npp.2013.92",
language = "English (US)",
volume = "38",
pages = "1854--1863",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Springer Nature",
number = "10",
}